Incyte also has an MFN deal Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 2 September, 2026

Twenty new honorees join the 140-plus women Endpoints News has recognized for reshaping biopharma. How did they get there, and what's changed? Join us for exclusive interviews, in-depth profiles and a frank look at gender representation in the industry today. Register now.

presented by How the Riyadh Glob­al Med­ical Biotech­nol­o­gy Sum­mit is de-risk­ing Sau­di Ara­bi­a's cell and gene ther­a­py am­bi­tions

SPOTLIGHT Take the Q3 Biopharma Sentiment Survey (BPSI)

news Exclusive: Typewriter raises $56M for jumping-gene tech, in vivo CAR-T Three takeaways from the latest White House drug pricing event ARPA-H awards $125M for manufacturing custom RNA therapies on demand

Sep 03 11:00 am ET How leading pharma organizations are putting AI agents to work sponsored by Medable Sep 10 11:00 am ET Inside the IDMO model: Analytical comparability, regulatory readiness and operational excellence sponsored by Cellares Sep 16 2:00 pm ET Beyond ICD codes: Unlocking rare disease insights with genomics and claims-based data sponsored by GeneDx Sep 22 12:00 pm ET The future of drug pricing: Medicare negotiation, MFN models & beyond sponsored by ADVI Oct 22 11:00 am ET A new model for clinical research – Expanding community trial access sponsored by Parexel

One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.

ENDPOINTS PHARMA Novartis' Rhapsido safer than rivals, Phase 3 multiple sclerosis data suggest Arsenal Biosciences cuts ‘majority’ of staff in move to in vivo CAR-T GSK to launch Phase 3 test of mRNA flu vaccine with newer formulation

in case you missed it 1. Lilly’s dealmaking spreads the wealth among a broad set of biotech venture investors 2. Roche signs trispecific T cell engager pact with Simcere in another China deal 3. Alumis falls after TYK2 pill fails lupus study, but CEO sees 'clear path forward' 4. ARCH Venture Partners targets $3 billion raise for latest fund 5. Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused